{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"58.89","upperLimit":"67.74","value":"63.50"},{"groupId":"OG001","lowerLimit":"51.52","upperLimit":"60.47","value":"56.13"}]}],"title":"RFS Rate at 1 Year"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"46.69","upperLimit":"56.00","value":"51.45"},{"groupId":"OG001","lowerLimit":"39.27","upperLimit":"48.28","value":"43.83"}]}],"title":"RFS Rate at 2 Years"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"41.46","upperLimit":"51.34","value":"46.48"},{"groupId":"OG001","lowerLimit":"30.12","upperLimit":"39.50","value":"34.79"}]}],"title":"RFS Rate at 3 Years"}],"denoms":[{"counts":[{"groupId":"OG000","value":"475"},{"groupId":"OG001","value":"476"}],"units":"Participants"}],"description":"Yearly recurrence-free survival rates, eg. at 1 year, defined as the probability that a participant was recurrence-free at 1 year following randomization, were estimated for each treatment group using the Kaplan-Meier product-limit method, along with their corresponding log-log transformed 95% confidence intervals. RFS was defined as the time between the date of randomization and the date of first recurrence or death (whatever the cause), whichever occurred first. A participant who died without reported recurrence was considered to have recurrence on the date of death. For those who remained alive and recurrence-free, RFS was censored on the date of last evaluable post-randomization tumor assessment. For those who remained alive and had no recorded post-randomization tumor assessment, RFS was censored on the day of randomization. Participants with disease at baseline were considered to have an event on the day of randomization. CT and MRI were mandatory to establish recurrence.","dispersionType":"95% Confidence Interval","groups":[{"description":"Ipilimumab (10 mg/kg) as a single dose via a 90 minute intravenous (IV) infusion (not as bolus or IV push) during Days 1, 22, 43 and 64 (every 21 days in the Induction Phase) for a total of four separate doses, until disease recurrence, unacceptable toxicity or withdrawal of consent. During the maintenance phase, Ipilimumab was administered at a dose of 10 mg/kg, by IV infusion, every 12 weeks, beginning at Week 24, until disease recurrence, unacceptable toxicity or withdrawal of consent, for a maximum of 3 years (Week 156).","id":"OG000","title":"Ipilimumab 10mg/kg"},{"description":"Placebo as a single dose via a 90 minute intravenous (IV) infusion (not as bolus or IV push) during Days 1, 22, 43 and 64 (Induction Phase) for a total of four separate doses, until disease recurrence, unacceptable toxicity or withdrawal of consent. During the maintenance phase, placebo was administered by IV infusion every 12 weeks, beginning at Week 24, until disease recurrence, unacceptable toxicity or withdrawal of consent, for a maximum of 3 years (Week 156).","id":"OG001","title":"Placebo"}],"paramType":"NUMBER","populationDescription":"Intent-to-treat population: All randomized participants, analyzed in the arm to which they were allocated by randomization","reportingStatus":"POSTED","timeFrame":"At years 1, 2, and 3","title":"Recurrence-Free Survival (RFS) Rates Per IRC at 1 Year, 2 Years, and 3 Years in the ITT Population","type":"PRIMARY","unitOfMeasure":"Percentage of participants"}